WW International, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WW research report →
Range $25 – $25
Price Chart
About the company
WW International, Inc. , founded in 1961 and based in New York, New York, is a leading global provider of services and goods aimed at weight management and overall wellness. The company, which operated as Weight Watchers International, Inc.
- CEO
- Felicia DellaFortuna
- IPO
- 2001
- Employees
- 3,500
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on WW
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $69.69M
- P/E
- -3.00
- Fwd P/E
- 34.85
- PEG
- 0.03
- P/S
- 0.13
- P/B
- 0.29
- EV/EBITDA
- 5.03
- Div Yield
- 0.00%
- Gross Margin
- 67.36%
- Op Margin
- 0.54%
- Net Margin
- -4.44%
- ROE
- -9.92%
- ROIC
- 0.35%
Latest fiscal year · YoY change
- Revenue
- $710.64M-9.6%
- Gross Profit
- $510.50M-4.2%
- Op Income
- $46.43M
- Net Income
- $1.06B+405.5%
- EPS
- $105.69+126.1%
- OCF Growth
- -71.6%
- FCF Growth
- -39.5%
- 52W High
- $35.25
- 52W Low
- $6.83
- 50D MA
- $13.76
- 200D MA
- $15.35
- Beta
- 1.88
- RSI (14)
- 26
- Avg Volume
- 274.91K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
WeightWatchers said Q3 showed improving mix and profitability as Core+ and Med+ grew, helping offset a smaller Core base and setting up a stronger 2026 outlook.· November 5, 2026
- Core+ grew for a fourth straight quarter, while Core+ and Med+ now generate roughly half of revenue.
- Clinical revenue rose 48% year over year, but clinical subscribers fell sequentially as the company lapped last year’s compounded semaglutide transition.
- Adjusted EBITDA hit $51.7 million with a 33.8% margin, and operating cash flow was positive at $32.3 million.
- Management narrowed full-year 2026 guidance and raised expected gross margin to about 74%.
- New CEO Stephen Bye emphasized discipline, member support, and a path back to sustainable profitable growth in 2027.
Third-quarter revenue was $152.9 million, down 11% from $172.1 million a year ago. Adjusted EBITDA was $51.7 million, up 21% year over year, with a 33.8% margin versus 24.9% in Q3 2025. Adjusted gross margin improved to 74.6%; net income was $15.1 million; and operating cash flow was $32.3 million. Total subscribers ended at about 2.3 million, with behavioral subscribers at about 2.1 million, down 26% year over year, Core+ subscribers at 546,000, and clinical subscribers at 174,000, up 40% year over year but down from 197,000 at the end of June. For the full year 2026, the company narrowed guidance to revenue of $625 million-$630 million and adjusted EBITDA of $110 million-$115 million. It now expects full-year adjusted gross margin of approximately 74%, clinical subscription revenue to be about 25% of full-year revenue, and positive operating cash flow, with projected interest costs of approximately $45 million-$50 million.
Stephen Bye framed the company as a support-driven platform positioned to benefit as GLP-1 access broadens and the need for behavioral and nutritional guidance grows. He said WeightWatchers has a differentiated offering across Core+, Med+, and workshops, and stressed that the company’s job is to reduce friction, improve the member experience, and grow profitably. His tone was candid but optimistic: he said the business is not yet living up to its potential, but he believes it is well positioned to return to sustainable profitable growth in 2027.
Felicia DellaFortuna highlighted that Core+ and Med+ now account for roughly half of revenue, with Core+ subscribers up 16% year over year and clinical subscription revenue up more than 30% year over year in every quarter of 2026, including 48% in Q3. She cited stronger mix, workflow automation, and more efficient service delivery as reasons adjusted gross margin improved to 74.6%, while marketing spend fell to $33.1 million from $48.4 million a year ago and adjusted SG&A was about $25 million. She also noted $126.4 million of cash and cash equivalents at quarter end, more than 70% debt reduction since the June 2025 reorganization to $423.6 million, and said the company still expects positive full-year operating cash flow despite projected interest costs of about $45 million-$50 million.
Analysts focused on what is driving Core+ growth, whether that growth is coming from GLP-1 users outside WeightWatchers, and how sustainable the margin profile is as clinical becomes a larger share of revenue. Management said Core+ growth is coming from several sources, including more than doubling adoption of the GLP-1 Success Program since the start of the year, a 40% increase in participation in virtual experiences, and about 20% of signups migrating from Core. On margins, Felicia said the company has been able to hold gross margin around 74% despite a bigger clinical mix because of more efficient execution and better cost delivery. Questions also covered clinical subscriber declines, with management attributing the drop largely to lapping the one-year anniversary of the 12-month plans introduced during the semaglutide transition, and to more balanced marketing allocation across the portfolio.
The call showed momentum in higher-value offerings, with Core+ growing for a fourth straight quarter and clinical revenue up 48% year over year. Management believes GLP-1 expansion is enlarging the addressable market, and it pointed to positive evidence that members get better weight-loss results with WeightWatchers’ behavioral support. The company also has improved liquidity and lower debt, giving it more flexibility to invest while still generating cash.
Behavioral subscribers remain down 26% year over year, and clinical subscribers fell sequentially from Q2 as the company lapped transition-related plans. Management acknowledged that awareness for Med+ did not carry through the year as hoped, and said it needs a more diversified marketing approach. Bye also said the business is still not living up to its potential, implying there is meaningful execution work left before the 2027 profitability target.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 87.6%
- Shares Outstanding
- 10.00M
- Float Shares
- 8.75M
of shares held by institutions
81 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for WW, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Thomas Richard CarperSenate · DE | Buy | Aug 11, 21 | Filing → |
| Thomas Richard CarperSenate · DE | Sell | Nov 20, 20 | Filing → |
| Thomas Richard CarperSenate · DE | Sell | Nov 20, 20 | Filing → |
| Greg GianforteHouse · MT00 | Sell | Nov 12, 20 | Filing → |
| Thomas Richard CarperSenate · DE | Buy | Feb 27, 19 | Filing → |
| Greg GianforteHouse · MT00 | Buy | Mar 2, 20 | Filing → |
| Greg GianforteHouse · MT00 | Buy | May 13, 19 | Filing → |
| Greg GianforteHouse · MT00 | Buy | May 14, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cooper Creek Partners Management LLC | 961.72K | ▼ 13.70K |
| Aristeia Capital, L.L.C. | 705.64K | ▼ 42.84K |
| Millennium Management LLC | 561.54K | ▼ 86.84K |
| Ubs Group AG | 539.58K | ▼ 27.78K |
| Carronade Capital Management, LP | 467.58K | ▲ 10.86K |
| Fund 1 Investments, LLC | 422.47K | ▼ 357.16K |
| Vanguard Capital Management LLC | 419.61K | ▼ 1.35K |
| Cygnus Capital Advisors, LLC | 388.65K | ▲ 190.44K |
| Blackrock, Inc. | 307.56K | ▼ 4.09K |
| Prelude Capital Management, LLC | 294.74K | ▲ 192.46K |
| 683 Capital Management, LLC | 242.02K | ▲ 92.02K |
| Aegon Usa Investment Management, LLC | 230.12K | 0 |
Held by 48 ETFs
Biggest fund positions in WW by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | BYE STEPHEN J | buy | 12,500 |
| Nov 10, 26 | Gavales Lisa A | buy | 5,000 |
| Oct 1, 26 | BYE STEPHEN J | other | 63,134 |
| Oct 1, 26 | BYE STEPHEN J | other | 0 |
| Aug 18, 26 | Sjoqvist Nikolaj H | buy | 7,235 |
| Aug 10, 26 | GOVE SUE | other | 8,132 |
| Aug 10, 26 | Sjoqvist Nikolaj H | other | 8,132 |
| Aug 10, 26 | DAVIS EUGENE I | other | 8,132 |
| Aug 10, 26 | Gavales Lisa A | other | 8,132 |
| Aug 10, 26 | Hawks Carney | other | 8,132 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our WW coverage
Recent articles, reports, and earnings notes.
No research on WW yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate WW report →Weight Watchers Announces Discounted Prepayment Solicitation to Utilize Up to $10 Million to Reduce Term Loan Debt
globenewswire.com · Nov 17
What WW International (WW) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
WW International, Inc. (WW) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
Compared to Estimates, WW International, Inc. (WW) Q3 Earnings: A Look at Key Metrics
zacks.com · Nov 5
WW International, Inc. (WW) Surpasses Q3 Earnings Estimates
zacks.com · Nov 5
Weight Watchers Announces Third Quarter 2026 Results
globenewswire.com · Nov 5
WW International, Inc. (WW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
zacks.com · Oct 29
Is the Options Market Predicting a Spike in WW International Stock?
zacks.com · Oct 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.